[go: up one dir, main page]

EE04996B1 - Reguleeritud vabanemisega galantamiinipreparaat, meetod selle valmistamiseks, seda sisaldav doseerimisvorm ning farmatseutiline pakend - Google Patents

Reguleeritud vabanemisega galantamiinipreparaat, meetod selle valmistamiseks, seda sisaldav doseerimisvorm ning farmatseutiline pakend

Info

Publication number
EE04996B1
EE04996B1 EEP200100319A EEP200100319A EE04996B1 EE 04996 B1 EE04996 B1 EE 04996B1 EE P200100319 A EEP200100319 A EE P200100319A EE P200100319 A EEP200100319 A EE P200100319A EE 04996 B1 EE04996 B1 EE 04996B1
Authority
EE
Estonia
Prior art keywords
preparation
dosage form
controlled release
pharmaceutical packaging
galantamine
Prior art date
Application number
EEP200100319A
Other languages
English (en)
Estonian (et)
Inventor
Paul Mcgee John
Marie Victor Gilis Paul
Maurice Germain De Weer Marc
Florent Victor De Cond Valentin
Johannes Catherina De Bruijn Herman
Anne Rodolf Van Dycke Frederic
Original Assignee
Janssen Pharmaceutica N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8234559&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE04996(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica N.V. filed Critical Janssen Pharmaceutica N.V.
Publication of EE200100319A publication Critical patent/EE200100319A/xx
Publication of EE04996B1 publication Critical patent/EE04996B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
EEP200100319A 1998-12-24 1999-12-20 Reguleeritud vabanemisega galantamiinipreparaat, meetod selle valmistamiseks, seda sisaldav doseerimisvorm ning farmatseutiline pakend EE04996B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP98204447 1998-12-24
PCT/EP1999/010257 WO2000038686A1 (en) 1998-12-24 1999-12-20 Controlled release galantamine composition

Publications (2)

Publication Number Publication Date
EE200100319A EE200100319A (et) 2002-10-15
EE04996B1 true EE04996B1 (et) 2008-04-15

Family

ID=8234559

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200100319A EE04996B1 (et) 1998-12-24 1999-12-20 Reguleeritud vabanemisega galantamiinipreparaat, meetod selle valmistamiseks, seda sisaldav doseerimisvorm ning farmatseutiline pakend

Country Status (35)

Country Link
US (3) US7160559B1 (xx)
EP (1) EP1140105B1 (xx)
JP (1) JP2002533396A (xx)
KR (1) KR100437105B1 (xx)
CN (1) CN100370990C (xx)
AP (1) AP1414A (xx)
AR (2) AR022008A1 (xx)
AT (1) ATE252386T1 (xx)
AU (1) AU775914B2 (xx)
BG (1) BG65306B1 (xx)
BR (1) BR9916835A (xx)
CA (1) CA2358062C (xx)
CZ (1) CZ301658B6 (xx)
DE (1) DE69912311T2 (xx)
DK (1) DK1140105T3 (xx)
EA (1) EA004936B1 (xx)
EE (1) EE04996B1 (xx)
ES (1) ES2211215T3 (xx)
HR (1) HRP20010463B1 (xx)
HU (1) HUP0104778A3 (xx)
ID (1) ID29021A (xx)
IL (2) IL143899A0 (xx)
MY (1) MY122411A (xx)
NO (1) NO327988B1 (xx)
NZ (1) NZ511643A (xx)
OA (1) OA11740A (xx)
PL (1) PL349501A1 (xx)
PT (1) PT1140105E (xx)
SI (1) SI1140105T1 (xx)
SK (1) SK287676B6 (xx)
TR (1) TR200101822T2 (xx)
TW (1) TWI262079B (xx)
UA (1) UA79578C2 (xx)
WO (1) WO2000038686A1 (xx)
ZA (1) ZA200105132B (xx)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2311441A1 (en) 1998-11-23 2011-04-20 Bonnie M. Davis Dosage formulations for acetylcholinesterase inhibitors
DK1140105T3 (da) 1998-12-24 2004-02-23 Janssen Pharmaceutica Nv Galantaminpræparat med styret frigivelse
CA2310926C (en) * 2000-04-03 2002-10-15 Janssen Pharmaceutica N.V. A use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's disease
CA2310950C (en) * 2000-04-03 2005-11-08 Janssen Pharmaceutica N.V. An efficacious dosage regiment of galantamine that reduces side effects
DE10134038A1 (de) * 2001-07-12 2003-02-06 Hf Arzneimittelforsch Gmbh Wirkstoff-Kombination zur medikamentösen Therapie der Nikotinabhängigkeit
AU2002340232A1 (en) * 2001-10-17 2003-04-28 Eisai Co., Ltd. Methods for treating substance abuse with cholinesterase inhibitors
FR2842735B1 (fr) 2002-07-26 2006-01-06 Flamel Tech Sa Microcapsules a liberation modifiee de principes actifs peu solubles pour l'administration per os
DE10235556A1 (de) * 2002-08-03 2004-02-19 Hf Arzneimittelforschung Gmbh Medikament und Verfahren zur Verringerung des Alkohol- und/oder Tabakkonsums
DK3473251T3 (da) 2002-12-20 2024-01-22 Niconovum Ab Nikotin-cellulose-kombination
ITMI20030827A1 (it) * 2003-04-18 2004-10-19 Unihart Corp Composizione farmaceutica contenente l'associazione levodopa/carbidopa.
US7250258B2 (en) 2003-12-15 2007-07-31 Pgxhealth Llc CDK5 genetic markers associated with galantamine response
CA2552114A1 (en) * 2003-12-31 2005-07-21 Actavis Group Hf Solid dosage formulations of galantamine
EP2340813A1 (en) * 2003-12-31 2011-07-06 Actavis Group PTC ehf. Solid dosage formulations of galantamine
EP1763337A2 (en) * 2003-12-31 2007-03-21 Actavis Group HF Immediate, controlled and sustained release formulations of galanthamine
GB0408308D0 (en) * 2004-04-14 2004-05-19 Vectura Ltd Pharmaceutical compositions
US20060280789A1 (en) * 2004-12-27 2006-12-14 Eisai Research Institute Sustained release formulations
US8481565B2 (en) * 2004-12-27 2013-07-09 Eisai R&D Management Co., Ltd. Method for stabilizing anti-dementia drug
US20090208579A1 (en) * 2004-12-27 2009-08-20 Eisai R & D Management Co., Ltd. Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same
US20070129402A1 (en) * 2004-12-27 2007-06-07 Eisai Research Institute Sustained release formulations
JP5597343B2 (ja) * 2005-04-28 2014-10-01 エーザイ・アール・アンド・ディー・マネジメント株式会社 抗痴呆薬を含有する組成物
EP1933816A1 (en) * 2005-09-05 2008-06-25 Ranbaxy Laboratories, Ltd. Galantamine-containing controlled release oral dosage forms, processes for the preparation thereof and use for the manufacture of a medicament
US20070092568A1 (en) * 2005-10-10 2007-04-26 Gore Subhash P Galantamine compositions
CA2646942C (en) 2006-03-16 2014-07-29 Niconovum Ab Improved snuff composition
SI2010158T1 (sl) * 2006-04-26 2016-08-31 Alphapharm Pty Ltd. Nadzorovane formulacije sproščanja obsegajoče neoplaščeno(e) diskretno(e) enoto(e) in razširjena matrika sproščanja
WO2008062426A2 (en) * 2006-08-02 2008-05-29 Emcure Pharmaceuticals Limited Formulation of benzazepine derivatives
US7955622B2 (en) 2006-10-13 2011-06-07 Actavis Group Ptc Hf Controlled-release galantamine formulations
DE102006056697A1 (de) * 2006-11-30 2008-06-05 Ratiopharm Gmbh Galanthamin-haltiges Arzneimittel mit kontrollierter Freisetzung
EP2120878B1 (en) * 2007-02-09 2014-07-30 Alphapharm PTY LTD A dosage form containing two active pharmaceutical ingredients in different physical forms
KR100782310B1 (ko) 2007-03-22 2007-12-06 현대약품 주식회사 갈란타민 또는 이의 약학적으로 허용 가능한 염을 포함하는약학 조성물
US20090035370A1 (en) * 2007-08-02 2009-02-05 Drugtech Corporation Dosage form and method of use
WO2009024858A1 (en) * 2007-08-22 2009-02-26 Aurobindo Pharma Limited Controlled release dosage form of galantamine
WO2009043914A1 (en) * 2007-10-05 2009-04-09 Krka, D.D., Novo Mesto Multi particulate matrix system containing galantamine
EP2044933A1 (en) * 2007-10-05 2009-04-08 KRKA, D.D., Novo Mesto Multi particulate matrix system containing galantamine
CA2615137A1 (en) * 2007-12-17 2009-06-17 Pharmascience Inc. Single layered controlled release therapeutic system
ATE545410T1 (de) * 2008-05-09 2012-03-15 Ratiopharm Gmbh Galanthaminhaltiges arzneimittel mit kontrollierter freisetzung
US9925282B2 (en) 2009-01-29 2018-03-27 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
EP2503996A2 (en) 2009-11-26 2012-10-03 USV Limited Controlled release pharmaceutical compositions of galantamine
WO2011151359A1 (en) 2010-06-02 2011-12-08 Noscira, S.A. Combined treatment with a cholinesterase inhibitor and a thiadiazolidinedione derivative
GR1007767B (el) 2011-07-26 2012-11-19 Φαρματεν Αβεε, Φαρμακευτικο σκευασμα παρατεταμενης αποδεσμευσης περιεχον γκαλανταμινη και μεθοδος για την παρασκευη αυτου
CA2889446C (en) 2012-10-25 2021-05-11 The General Hospital Corporation Combination therapies for the treatment of alzheimer's disease and related disorders
US10058530B2 (en) 2012-10-25 2018-08-28 The General Hospital Corporation Combination therapies for the treatment of Alzheimer's disease and related disorders
US10525005B2 (en) 2013-05-23 2020-01-07 The General Hospital Corporation Cromolyn compositions and methods thereof
TW201540301A (zh) 2013-08-16 2015-11-01 Takeda Gmbh 以ｐｄｅ４抑制劑治療認知損傷
AU2014340182B2 (en) 2013-10-22 2019-05-23 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
US9849125B1 (en) 2015-11-03 2017-12-26 Banner Lifie Sciences LLC Anti-overingestion dosage forms
GB201620095D0 (en) * 2016-11-28 2017-01-11 Terali Innov Sas And Univ De Strasbourg And Inserm (Inst Nat De La Sante Et De La Rech Medicale) And Novel use
JP2019524865A (ja) 2016-08-31 2019-09-05 ザ ジェネラル ホスピタル コーポレイション 神経変性疾患と関連する神経炎症におけるマクロファージ／ミクログリア
CA3064006C (en) 2017-05-19 2025-09-16 Biscayne Neurotherapeutics, Inc. Modified-Release Pharmaceutical Compositions of Huperzine and Their Methods of Use
US10335375B2 (en) 2017-05-30 2019-07-02 Patheon Softgels, Inc. Anti-overingestion abuse deterrent compositions
KR20210070232A (ko) 2017-07-20 2021-06-14 아즈테라피즈 인코포레이티드 크로몰린 나트륨 및 이부프로펜의 분말화된 제형
US20190247331A1 (en) 2018-02-15 2019-08-15 Osmotica Kereskedelmi és Szolgáltató Korlátolt Felelõsségû Társaság Composition and method for treating neurological disease
US10213394B1 (en) 2018-02-15 2019-02-26 Osmotica Kereskedelmi és Szolgáltató Korlátolt Felelõsségû Társaság Composition and method for treating neurological disease
US10213393B1 (en) 2018-02-15 2019-02-26 Osmotica Kereskedelmi és Szolgáltató Korlátolt Feleõsségû Társaság Composition and method for treating neurological disease
CN113038944A (zh) 2018-07-02 2021-06-25 通用医疗公司 色甘酸钠和α-乳糖的粉末化制剂
EP4541419A3 (en) 2018-11-19 2025-05-07 Supernus Pharmaceuticals, Inc. Use of higher doses of modified release huperzine formulations
AU2019397436A1 (en) 2018-12-10 2021-07-22 The General Hospital Corporation Cromolyn esters and uses thereof
BG67408B1 (bg) 2019-04-12 2022-01-17 Софарма Ад Перорален лекарствен състав с растителен алкалоид, за лечение на зависимости
IL297023A (en) 2020-04-06 2022-12-01 Massachusetts Gen Hospital Methods for treating inflammatory conditions caused by the corona virus

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE450087B (sv) * 1985-10-11 1987-06-09 Haessle Ab Korn med kontrollerad frisettning av farmaceutiskt aktiva emnen som anbringats teckande pa ett kompakt olosligt kernmaterial
US4663318A (en) * 1986-01-15 1987-05-05 Bonnie Davis Method of treating Alzheimer's disease
AU632458B2 (en) 1987-05-04 1993-01-07 Bonnie Davis Compounds for the treatment of alzheimer's disease
CA1326632C (en) * 1988-10-26 1994-02-01 Bonnie Davis Long-active drug formulations comprising galanthamine for treatment of alzheimer's disease
US5085865A (en) * 1989-04-12 1992-02-04 Warner-Lambert Company Sustained release pharmaceutical preparations containing an analgesic and a decongestant
US5133974A (en) * 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5519017A (en) 1990-03-29 1996-05-21 Lts Lohmann Therapie-Systeme Gmbh + Co. Kg Pharmaceutic formulation for the treatment of alcoholism
DE4010079A1 (de) * 1990-03-29 1991-10-02 Lohmann Therapie Syst Lts Pharmazeutische formulierung zur behandlung des alkoholismus
AT397345B (de) 1990-04-04 1994-03-25 Chemiefaser Lenzing Ag Pharmazeutisches präparat mit verzögerter wirkstofffreisetzung auf basis von hemicellulosen
JP2542122B2 (ja) * 1990-04-18 1996-10-09 旭化成工業株式会社 球状核、球形顆粒およびその製造方法
NZ242744A (en) 1991-05-14 1997-02-24 Ernir Snorrason Use of a cholinesterase inhibitor (eg a galanthamine derivative) for treating fatigue
US5336675A (en) * 1991-05-14 1994-08-09 Ernir Snorrason Method of treating mania in humans
US5213811A (en) * 1991-09-13 1993-05-25 Sterling Drug Inc. Oral sustained-release drug compositions
US5229135A (en) * 1991-11-22 1993-07-20 Prographarm Laboratories Sustained release diltiazem formulation
DE4301783C1 (de) * 1993-01-23 1994-02-03 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit Galanthamin als wirksamem Bestandteil
DE4301782C1 (de) 1993-01-23 1994-08-25 Lohmann Therapie Syst Lts Verwendung von Galanthamin zur Behandlung der Nicotinabhängigkeit
HU219462B (hu) * 1993-06-14 2001-04-28 Janssen Pharmaceutica N.V. Asztemizolt és pszeudoefedrint tartalmazó, nyújtott hatású, filmbevonatos tabletták
DE4319760A1 (de) * 1993-06-15 1994-12-22 Bayer Ag Ipsapiron Arzneimittelzubereitung
JPH09500645A (ja) * 1993-07-22 1997-01-21 ワーナー−ランバート・コンパニー 制御放出タクリン薬物送達システムおよびその製造方法
EP0647448A1 (en) * 1993-10-07 1995-04-12 Euroceltique S.A. Orally administrable opioid formulations having extended duration of effect
US6323196B1 (en) 1993-10-15 2001-11-27 Aventis Pharmaceuticals Inc. Galanthamine derivatives as acetylcholinesterase inhibitors
US6323195B1 (en) 1993-10-15 2001-11-27 Aventis Pharmaceuticals Inc. Galanthamine derivatives as acetylcholinesterase inhibitors
DE4342174C1 (de) * 1993-12-10 1995-05-11 Lohmann Therapie Syst Lts Transdermales therapeutisches System sowie ein Verfahren zur Herstellung eines transdermalen therapeutischen Systems zur kombinierten transdermalen Anwendung von Physostigmin und Scopolamin für die Prophylaxe und zur Vorbehandlung einer Vergiftung durch hochtoxische phosphororganische Nervengifte, insbesondere Soman und seine Verwendung
US5558879A (en) * 1995-04-28 1996-09-24 Andrx Pharmaceuticals, Inc. Controlled release formulation for water soluble drugs in which a passageway is formed in situ
GB9514821D0 (en) 1995-07-19 1995-09-20 Sod Conseils Rech Applic Galanthamine derivatives
JP3833314B2 (ja) * 1995-09-08 2006-10-11 武田薬品工業株式会社 発泡性組成物およびその製造方法
JP3693270B2 (ja) 1995-10-12 2005-09-07 旭化成ケミカルズ株式会社 フィルムコーティング顆粒およびその製造方法
SE9504537D0 (sv) * 1995-12-19 1995-12-19 Jan Hedner Sätt att behandla och diagnosticera andningsstörningar under sömn och medel för utförande av sättet
JP3134187B2 (ja) 1996-03-07 2001-02-13 武田薬品工業株式会社 放出制御組成物
TW506836B (en) 1996-06-14 2002-10-21 Janssen Pharmaceutica Nv Fast-dissolving galanthamine hydrobromide tablet
SK66199A3 (en) * 1996-11-19 2000-02-14 Procter & Gamble Compliance package and method of improving or aiding patient compliance for complex drug regimens
JPH10231242A (ja) * 1997-02-20 1998-09-02 Taiyo Yakuhin Kogyo Kk 持続性ジクロフェナクナトリウム組成物
GB9711643D0 (en) * 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
TW477702B (en) * 1997-10-23 2002-03-01 Dev Center Biotechnology Controlled release tacrine dosage form
WO1999021561A1 (en) 1997-10-29 1999-05-06 Davis Bonnie M Method for treatment of disorders of attention
EP2311441A1 (en) 1998-11-23 2011-04-20 Bonnie M. Davis Dosage formulations for acetylcholinesterase inhibitors
DK1140105T3 (da) 1998-12-24 2004-02-23 Janssen Pharmaceutica Nv Galantaminpræparat med styret frigivelse
AUPP891299A0 (en) 1999-02-26 1999-03-25 Fujisawa Pharmaceutical Co., Ltd. New 6-membered cyclic compounds
US6273260B1 (en) * 2000-03-08 2001-08-14 Eli Lilly And Company Pharmaceutical packaging system

Also Published As

Publication number Publication date
EP1140105B1 (en) 2003-10-22
BR9916835A (pt) 2001-09-25
US20060093671A1 (en) 2006-05-04
EA004936B1 (ru) 2004-10-28
CA2358062C (en) 2006-12-19
NO20012857L (no) 2001-06-08
HRP20010463B1 (hr) 2011-02-28
NO20012857D0 (no) 2001-06-08
AP1414A (en) 2005-06-13
AR066313A2 (es) 2009-08-12
AU2100600A (en) 2000-07-31
KR20010075715A (ko) 2001-08-09
AP2001002219A0 (en) 2001-09-30
DE69912311D1 (de) 2003-11-27
HK1043062A1 (zh) 2002-09-06
KR100437105B1 (ko) 2004-06-23
CN1331596A (zh) 2002-01-16
EE200100319A (et) 2002-10-15
TWI262079B (en) 2006-09-21
ZA200105132B (en) 2002-06-21
UA79578C2 (en) 2007-07-10
HUP0104778A2 (hu) 2002-04-29
ID29021A (id) 2001-07-26
NO327988B1 (no) 2009-11-02
DE69912311T2 (de) 2004-07-29
CA2358062A1 (en) 2000-07-06
ES2211215T3 (es) 2004-07-01
OA11740A (en) 2005-05-13
DK1140105T3 (da) 2004-02-23
EP1140105A1 (en) 2001-10-10
JP2002533396A (ja) 2002-10-08
CN100370990C (zh) 2008-02-27
US20060062856A1 (en) 2006-03-23
SK287676B6 (sk) 2011-05-06
US7160559B1 (en) 2007-01-09
CZ20012182A3 (cs) 2002-01-16
HUP0104778A3 (en) 2004-05-28
AU775914B2 (en) 2004-08-19
SK8862001A3 (en) 2002-02-05
PL349501A1 (en) 2002-07-29
MY122411A (en) 2006-04-29
NZ511643A (en) 2003-07-25
HRP20010463A2 (en) 2002-08-31
CZ301658B6 (cs) 2010-05-19
IL143899A0 (en) 2002-04-21
WO2000038686A1 (en) 2000-07-06
IL143899A (en) 2006-04-10
EA200100713A1 (ru) 2001-12-24
SI1140105T1 (en) 2004-04-30
BG65306B1 (bg) 2008-01-31
TR200101822T2 (tr) 2001-11-21
AR022008A1 (es) 2002-09-04
BG105564A (en) 2002-01-31
PT1140105E (pt) 2004-03-31
ATE252386T1 (de) 2003-11-15

Similar Documents

Publication Publication Date Title
EE200100319A (et) Reguleeritud vabanemisega galantamiinipreparaat, meetod selle valmistamiseks, seda sisaldav doseerimisvorm ning farmatseutiline pakend
EE03902B1 (et) Osakesed, nende valmistamismeetod ja kasutamine, farmatseutiline doseerimisvorm ja selle valmistamismeetod, tahke dispersioon ning farmatseutiline pakend
EE05232B1 (et) Reguleeritud vabastamisega graanul, meetod selle valmistamiseks ning seda sisaldav mitmehikuline ravimvorm
LTPA2014005I1 (lt) Chinazolidino dariniai, minėtus junginius turintys vaistai, jų panaudojimas ir jų gavimo būdas
EE05086B1 (et) Primidiini derivaadid, nende valmistamismeetod ja kasutamine, farmatseutiline kompositsioon ja selle valmistamismeetod, kombinatsioon ning saadus
EE200200151A (et) Osake, ravimvorm, nende valmistamismeetodid, osakeste kasutamine ning farmatseutiline pakend
PL396568A1 (pl) Krystaliczny bursztynian O-demetylo-wenlafaksyny, kompozycja farmaceutyczna, farmaceutyczna postać dawkowania, doustna postać dawkowania, zastosowanie oraz sposób wytwarzania krystalicznego bursztynianu O-demetylo-wenlafaksyny
EE9700328A (et) Tahke oraalne preparaat, mis sisaldab toimeainena olansapiini, selle valmistamismeetod ja kasutamine
HUP0200309A2 (en) Arylpiperazinyl-cyclohexyl indole derivatives for the treatment of depression, process for their preparation and pharmaceutical compositions containing them
IS5747A (is) Oxazólidínón afleiður, aðferð fyrir framleiðslu þeirra og lyfjasamsetninga sem innihalda þær
EE04417B1 (et) Peroraalne farmatseutiline pulseeriva vabanemisega annusvorm, selle valmistamise meetod ja kasutamine
EE9800269A (et) Tahke doseerimisvorm, selle valmistamismeetod, seda sisaldav produkt, tablett ja farmatseutiline pakend ning tsisapriidisoolade kasutamine
EE05214B1 (et) Polool-IFN- β konjugaat, selle valmistamismeetod ja farmatseutiline kompositsioon
ZA200110217B (en) Indole derivatives, process for their preparation, pharmaceutical compositions containing them and their medicinal application.
EE05506B1 (et) Ravimi manustamise vahend eriti progestiinide ja”strogeenide manustamiseks
EE200300207A (et) Heterotsüklüülalküülpiperidiini derivaadid, nendevalmistamismeetodid ja farmatseutiline kompositsioon
PL333524A1 (en) Improved prolonged release pharmaceutic preparation for administration of nephadosone, oral dosage form thereof and improved nephadosone administration method
EE05242B1 (et) 5-kloro-3-(4-metaansulfonlfenl)-6'-metl[2,3']bipridinli polmorfne vorm, selle valmistamismeetod, kasutamine ja farmatseutiline kompositsioon
EE9900162A (et) Rinnavähi vältimise meetod, farmatseutiline preparaat ja toode ning toimeaine kasutamine
EE200200199A (et) N-guanidinoalküülamiid, meetod selle valmistamiseks, seda sisaldav farmatseutiline preparaat ning raviotstarbeline kasutamine
EE9800075A (et) Kombineeritud ravimpreparaat, selle kasutamine ja meetod selle valmistamiseks
EE200000569A (et) PDE IV inhibeerivad püridiini derivaadid, nende valmistamismeetod ja kasutamine ning farmatseutiline kompositsioon ja selle valmistamismeetod
EE200000796A (et) Ravimkuulike, selle valmistamismeetod ja farmatseutiline doseerimisvorm, ravimkuulikeste kasutaminefarmatseutilise doseerimisvormi valmistamiseks ning farmatseutiline pakend
NO20012518L (no) Fremgangsmåte ved fremstilling av legemidler i fast administrasjonsform
NO975680L (no) Oralt, farmasöytisk preparat av piperidinoalkanol-forbindelser i opplösningsform

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20081231

KB4A Valid patent at the end of a year

Effective date: 20101231